Navigation Links
Biotech Company Relocates to State-of-the-Art Facility
Date:1/4/2011

HAMILTON, N.J., Jan. 4, 2011 /PRNewswire/ -- VENENUM Biodesign, a drug discovery company that utilizes ultra-high throughput screening (UHTS) of its compound collection to identify hits against its novel disease-based targets or its partners' targets, announced today its relocation to a brand-new, state-of-the-art facility in Hamilton, NJ in Mercer County.

VENENUM Biodesign was established with the mission to improve patients' lives through the discovery of new therapeutic compounds. They are committed to building platforms for drug discovery research from novel targets to preclinical implementation. VENENUM Biodesign, a company within the Genesis Biotechnology Group, is located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible to other academic medical centers, biotech, and pharmaceutical companies in the New York, New Jersey, and Pennsylvania area.

This new facility is a unique blend of upscale office space with state-of-the-art laboratory facilities designed with a specialized floor plan to accommodate the Biodesign compound collection which includes 5.5 million proprietary compounds (the "ECLiPS" collection), six newly designed VENENUM Targeted Libraries (VTLs), and approximately 80,000 compounds from commercial sources. This small molecule collection is one of the largest in the world and, combined with state-of-the-art UHTS capabilities, is a powerful tool to generate quality platforms for drug discovery.

There are expansive laboratories to accommodate mammalian and yeast cell culture, siRNA technology, protein engineering and production, cellular reagent generation, structural biology, and in vitro assay and in vivo model development. VENENUM Biodesign's new facility has been engineered to specifically accommodate their well-published and experienced Target Biology department which identifies and validates novel targets. They are currently completing additional laboratory space immediately adjacent to the Target Biology Division to accommodate a growing Medicinal Chemistry team which implements and executes Hit-to-Lead and Lead Optimization programs.

According to Dr. Maria Webb, Chief Scientific Officer (CSO), "Our intention is to use our drug discovery capabilities to develop our own novel targets into therapeutic products as well as to provide access of our core capabilities to other companies and research institutions."

To find out more, please visit http://www.venenumbiodesign.com.Contact:Maria Webb, Ph.D.Chief Scientific Officer (CSO)mwebb@venenumbiodesign.com609.570.1048http://www.venenumbiodesign.com  This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VENENUM Biodesign
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference
2. Interleukin Genetics, Inc. to Present at Biotech Showcase 2011
3. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
4. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
5. New Second Edition of Biotechnology and the Federal Circuit Examines the Courts Decisions on Chemical, Biotechnology, and Pharmaceutical Patent Law Cases
6. Biotech Guru G. Steven Burrill Offers his Predictions on What Lies Ahead for the Biotech Industry in 2011
7. BioCrossroads Invests in Innovative Biotech Targeting Challenging Diseases
8. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
9. Bunker Hill Community College Wins Major Endorsement for Biotechnology Courses
10. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
11. Reportlinker Adds Nanobiotechnology: Applications and Global Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... DIEGO , May 19, 2016 ... (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today ... creating the first cord blood based cancer immunotherapeutic ... provisional patent application, Regen described a generation of ... was potentiated by gene silencing.  The product in ...
(Date:5/18/2016)... ... May 18, 2016 , ... Tech Coast Angels (TCA) ... to Cognition Therapeutics at the annual ACA Summit last week in Philadelphia. ... one of ACA’s member angel groups. It is the highest honor available for an ...
(Date:5/18/2016)... May 18, 2016 The Biotech industry ... not mean that there are no opportunities ahead. Today, ActiveWallSt.com ... (NASDAQ: THLD ), Seattle Genetics Inc. (NASDAQ: ... and Ophthotech Corp. (NASDAQ: OPHT ). Sign up ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s ...
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, ... result of asthma complications.* Costing more than $56 billion in direct costs annually, ... , “For too many, the suffering associated with uncontrolled asthma can be overwhelmingly ...
Breaking Biology Technology:
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):